GLAXOSMITHKLINE PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of GLAXOSMITHKLINE PHARMACEUTICALS have increased by 6.21% YoY .
The Earnings Per Share (EPS) of GLAXOSMITHKLINE PHARMACEUTICALS has increased by 57.22 % YoY. |
||
GLAXOSMITHKLINE PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 500660|NSE : GLAXO]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹3,454 Cr | ₹3,252 Cr | ₹3,278 Cr | ₹2,926 Cr | ₹3,224 Cr |
| Expenses | ₹2,545 Cr | ₹2,447 Cr | ₹2,516 Cr | ₹2,327 Cr | ₹2,567 Cr |
| Operating Profit (Excl OI) | ₹909 Cr | ₹804 Cr | ₹762 Cr | ₹598 Cr | ₹657 Cr |
| Other Income | ₹123 Cr | ₹101 Cr | ₹76 Cr | ₹111 Cr | ₹79 Cr |
| Interest | ₹1.80 Cr | ₹1.81 Cr | ₹2.00 Cr | ₹3.53 Cr | ₹6.34 Cr |
| Depreciation | ₹70 Cr | ₹66 Cr | ₹68 Cr | ₹79 Cr | ₹83 Cr |
| Profit Before Tax | ₹816 Cr | ₹836 Cr | ₹779 Cr | ₹454 Cr | ₹306 Cr |
| Profit After Tax | ₹590 Cr | ₹608 Cr | ₹381 Cr | ₹287 Cr | ₹93 Cr |
| Consolidated Net Profit | ₹590 Cr | ₹611 Cr | ₹1,695 Cr | ₹358 Cr | ₹93 Cr |
| Earnings Per Share (Rs) | ₹54.76 | ₹34.83 | ₹36.05 | ₹100.04 | ₹21.14 |
| PAT Margin (%) | 22.50 | 15.59 | 18.69 | 10.59 | 9.19 |
| ROE(%) | 49.43 | 33.43 | 27.58 | 18.39 | 17.42 |
| ROCE(%) | 67.64 | 46.49 | 38.06 | 37.72 | 27.74 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 45,751.6 Cr |
| Revenue (TTM) | : | ₹ 3,800.7 Cr |
| Net Profit(TTM) | : | ₹ 1,021.0 Cr |
| EPS (TTM) | : | ₹ 60.3 |
| P/E (TTM) | : | 44.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLAXOSMITHKLINE PHARMACEUTICALS | 10.6% | 12.6% | 31.5% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.5% | -1.5% | -2.6% |
| DIVIS LABORATORIES | 5.5% | -0.2% | 0.8% |
| CIPLA | 1.3% | -7.9% | -6.6% |
| TORRENT PHARMACEUTICALS | 2.1% | 2.8% | 30.9% |
| DR REDDYS LABORATORIES | 2% | 4.5% | 2.3% |
| MANKIND PHARMA | 0.2% | -6.3% | -16.6% |
| ZYDUS LIFESCIENCES | -0.8% | 0.3% | -9.3% |
| LUPIN | -0.4% | 0.9% | 0.8% |
GLAXOSMITHKLINE PHARMACEUTICALS Revenues
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | 6.21 % |
| 5 Yr CAGR | 1.73 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹3,454 Cr | 6.21 | |
| Mar2024 | ₹3,252 Cr | -0.80 | |
| Mar2023 | ₹3,278 Cr | 12.05 | |
| Mar2022 | ₹2,926 Cr | -9.27 | |
| Mar2021 | ₹3,224 Cr | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Operating Profit
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | 12.98 % |
| 5 Yr CAGR | 8.44 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹909 Cr | 12.98 | |
| Mar2024 | ₹804 Cr | 5.57 | |
| Mar2023 | ₹762 Cr | 27.37 | |
| Mar2022 | ₹598 Cr | -8.99 | |
| Mar2021 | ₹657 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 6.39 % |
| 5 Yr CAGR | 6.59 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 26.31% | 6.39 | |
| Mar2024 | 24.73% | 6.41 | |
| Mar2023 | 23.24% | 13.64 | |
| Mar2022 | 20.45% | 0.34 | |
| Mar2021 | 20.38% | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Profit After Tax
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | -3.39 % |
| 5 Yr CAGR | 58.62 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹590 Cr | -3.39 | |
| Mar2024 | ₹611 Cr | -63.97 | |
| Mar2023 | ₹1,695 Cr | 373.19 | |
| Mar2022 | ₹358 Cr | 284.26 | |
| Mar2021 | ₹93 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 44.32 % |
| 5 Yr CAGR | 25.09 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 22.5 % | 44.32 | |
| Mar2024 | 15.59 % | -16.59 | |
| Mar2023 | 18.69 % | 76.49 | |
| Mar2022 | 10.59 % | 15.23 | |
| Mar2021 | 9.19 % | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | 57.22 % |
| 5 Yr CAGR | 26.86 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹55 | 57.22 | |
| Mar2024 | ₹35 | -3.38 | |
| Mar2023 | ₹36 | -63.96 | |
| Mar2022 | ₹100 | 373.23 | |
| Mar2021 | ₹21 | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 500660|NSE : GLAXO]
| Y-o-Y | 45.49 % |
| 5 Yr CAGR | 24.96 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 67.64% | 45.49 | |
| Mar2024 | 46.49% | 22.15 | |
| Mar2023 | 38.06% | 0.90 | |
| Mar2022 | 37.72% | 35.98 | |
| Mar2021 | 27.74% | - | |
GLAXOSMITHKLINE PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹2,700.8 |
| Current MarketCap | : | ₹ 45,751.6 Cr |
| Updated EOD on | : | Feb 11,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAXOSMITHKLINE PHARMACEUTICALS | 10.6% |
12.6% |
31.5% |
| SENSEX | 0.5% |
0.8% |
7.2% |
GLAXOSMITHKLINE PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE HEALTHCARE | 2.4% | -1.1% | 1.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALL HEALTHCARE | 2.2% | -2.5% | 4.1% |
| NIFTY 500 EQUAL WEIGHT | 1.7% | 1.3% | 6.7% |
| NIFTY MIDSMALLCAP 400 | 1.7% | 1.5% | 9.3% |
| NIFTY MIDCAP 150 | 1.7% | 1.7% | 12.7% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | 1.4% | 1.3% | 8.6% |
You may also like the below Video Courses
FAQ about GLAXOSMITHKLINE PHARMACEUTICALS Financials
How the annual revenues of GLAXOSMITHKLINE PHARMACEUTICALS have changed ?
The Revenues of GLAXOSMITHKLINE PHARMACEUTICALS have increased by 6.21% YoY .
How the Earnings per Share (EPS) of GLAXOSMITHKLINE PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of GLAXOSMITHKLINE PHARMACEUTICALS has increased by 57.22 % YoY .
Check out Intrinsic Value of Peers of GLAXOSMITHKLINE PHARMACEUTICALS
Compare Stock Analytics of Peers of GLAXOSMITHKLINE PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
